Healthcare
IDEXX Laboratories, Inc.(IDXX)
Live Price
Offline$562.09
+2.93% today
1Y Change
+5.97%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $44.65B
- Revenue Growth
- +10.4%
- EPS Growth
- +22.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
IDEXX Laboratories, Inc. (IDXX) is a Healthcare stock with a market cap of $44.65B and listed on NASDAQ. The stock last traded around $562.09 and up 6.0% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +10.4%, EPS growth of +22.3%, a dividend yield of 0.0%. What stands out right now is revenue +10.4%, EPS +22.3%, free cash flow +32.0% with operating margin 31.6% and ROIC 40.3%. Valuation already assumes a fairly strong business story at P/E 42.4 and price/sales 10.4. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines IDXX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.4% vs +7.6% peer median
Operating Margin
Above sector median
+31.6% vs +19.4% peer median
P/E
Above sector median
42.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +10.4% and EPS at +22.3%, with operating margin around 31.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -2.1% | -6.9% | -1.8% |
2026 Feb 2, 2026 | +5.1% | -1.1% | +0.0% | -0.6% |
2025 Nov 3, 2025 | +8.3% | -0.1% | -1.8% | +1.4% |
Benchmark Edge
IDXX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IDXX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IDXX Max Drawdown
-31.04%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IDXX and SPY.
Company Overview
IDEXX Laboratories, Inc.
NASDAQ Global Select
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
- Leadership
- Jonathan J. Mazelsky
- IPO Date
- Jun 21, 1991
- Employees
- 11.0k
- Street Address
- One IDEXX Drive
- Mailing
- Westbrook, ME, 04092
- Region
- Westbrook, ME, US
- Reporting Currency
- USD
- Investor Line
- 207 556 0300
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 42.4
- EV/EBITDA
- 30.2
- Price/Sales
- 10.4
- Price/Book
- 28.0
Growth
- Revenue
- +10.4%
- EPS
- +22.3%
- Free Cash Flow
- +32.0%
Profitability
- Gross Margin
- 61.8%
- Operating Margin
- 31.6%
- Net Margin
- 24.6%
- ROE
- 69.8%
- ROIC
- 40.3%
Balance Sheet
- Debt/Equity
- 0.67
- Current Ratio
- 1.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.